A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups

Journal of Human Genetics

Volumn 54, Issue 5, 2009, Pages 261-265

  Parathyras, John ^a   Gebhardt, Stefan ^b   Hillermann Rebello, Renate ^a   Grobbelaar, Nelis ^c   Venter, Mauritz ^a   Warnich, Louise ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c Paarl Hospital   (South Africa)

Author keywords

ABCB1; Antiretroviral therapy; CYP2B6; CYP3A4; South African populations

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; EFAVIRENZ; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ANALYSIS OF VARIANCE; ARTICLE; BACKACHE; CD4 LYMPHOCYTE COUNT; CEREBRAL BLINDNESS; CONTROLLED STUDY; CONVULSION; DIPLOPIA; DIZZINESS; DRUG RESPONSE; DRUG WITHDRAWAL; ETHNICITY; FATIGUE; GENETIC POLYMORPHISM; GENOTYPE; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPODYSTROPHY; MAJOR CLINICAL STUDY; NAUSEA; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PRURITUS; RASH; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AFRICA; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; ETHNIC GROUPS; GENE FREQUENCY; GENEALOGY AND HERALDRY; GENOTYPE; HIV INFECTIONS; HUMANS; PHARMACOGENETICS; SOUTH AFRICA;

EID: 67649517091     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1038/jhg.2009.20     Document Type: Article

References (38)

1. Carr, A. & Cooper, D. A. Adverse effects of antiretroviral therapy. Lancet 356, 853-860 (2000).
2. Quirk, E., McLeod, H. & Powderly, W. The pharmacogenetics of antiretroviral therapy: A review of studies to date. Clin. Infect. Dis. 39, 98-106 (2004).
3. Shibuyama, S., Gevorkyan, A., Yoo, U., Tim, S., Dzhangiryan, K. & Scott, J. D. Understanding and avoiding antiretroviral adverse events. Curr. Pharm. Design 12, 1075-1090 (2006).
4. Ingelman-Sundberg, M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med. 250, 186-200 (2001).
5. Hardy, B. J., Séguin, B., Goodsaid, F., Jimenez-Sanchez, G., Singer, P. A. & Daar, A. S. The next steps for genomic medicine: challenges and opportunities for the developing world. Nat. Rev. Genet. 9 (10s), S23-S27 doi:10.1038/nrg2444 (2008).
6. Haas, D. W. Will pharmacogenomic discoveries improve HIV therapeutics? Top. HIV Med. 13, 90-95 (2005).
7. Haas, D. W., Smeaton, L. M., Shafer, R. W., Robbins, G. K., Morse, G. D. & Labbé, L. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an adult AIDS clinical trials group study. J. Infect. Dis. 192, 1931-1942 (2005).
8. Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U. et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11, 399-415 (2001).
9. Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. R. & Gulick, R. M. et al. Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study. AIDS 18, 2391-2400 (2004).
10. Tsuchiya, K., Gatanaga, H., Tachikawa, N., Teruya, K., Kikuchi, Y., Yoshino, M. et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun. 319, 1322-1326 (2004).
11. Rodríguez-Nóvoa, S., Barreiro, P., Rendón, A., Jiménez-Nacher, I., Gonzalez-Lahoz, J. & Soriano, V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin. Infect. Dis. 40, 1358-1361 (2005).
12. Rotger, M., Colombo, S., Furrer, H., Bleiber, G., Buclin, T., Lee, B. L. et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15, 1-5 (2005).
13. Ribaudo, H. J., Haas, D. W., Tierney, C., Kim, R. B., Wilkinson, G. R., Gulick, R. M. et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an adult AIDS clinical trials group study. Clin. Infect. Dis. 42, 401-407 (2006).
14. Wang, J., Sonnerborg, A., Rane, A., Josephson, F., Lundgren, S., Stahle, L. et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 16, 191-198 (2006).
15. Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J. & Malkowicz, S. B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 90, 1225-1229 (1998).
16. Amirimani, B., Walker, A. H., Weber, B. L. & Rebbeck, T. R. RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 91, 1588-1590 (1999).
17. Ando, Y., Tateishi, T., Sekido, Y., Yamamoto, T., Satoh, T., Hasegawa, Y. et al. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 [letter; comment]. J. Natl Cancer Inst. 91, 1587-1590 (1999).
18. Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J. P. et al. Response to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359, 30-35 (2002).
19. Nasi, M., Borghi, V., Pinti, M., Bellodi, C., Lugli, E., Maffei, S. et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drugnaïve HIV-positive patients. AIDS 17, 1696-1698 (2003).
20. Winzer, R., Langmann, P., Zilly, M., Tollmann, F., Schubert, J., Klinker, H. et al. No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients. Ann. Clin. Microbiol. Antimicrob. 4, 3 (2005).
21. du Toit, E. D., MacGregor, K. J., Taljaard, D. G. & Oudshoorn, M. HLA-A, B, C, DR and DQ polymorphisms in three South African population groups: South African Negroes, Cape Coloureds and South African Caucasoids. Tissue Antigens 31, 109-125 (1988).
22. Nurse, G. T., Weiner, J. S. & Jenkins, T. (eds) The Growth of hybrid communities. in The Peoples of Southern Africa and their Affinities 218-224 (Clarendon Press, Oxford, 1985).
23. Miller, S. A., Dykes, D. D. & Polesky, H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1988).
24. Cavaco, I., Gil, J. P., Gil-Berlund, E. & Ribeiro, V. CYP3A4 and MDR1 alleles in a Portuguese population. Clin. Chem. Lab. Med. 41, 1345-1350 (2003).
25. Balram, C., Sharma, A., Sivathasan, C. & Lee, E. J. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br. J. Clin. Pharmacol. 56, 78-83 (2003).
26. Wegner, S., Vahey, M., Dolan, M., Wallace, M., Aronson, N., Barile, A. et al. Racial differences in clinical efficacy of efavirenz-based antiretroviral therapy. in Ninth Conference on Retroviruses and Opportunistic Infections (Seattle, WAFebruary 428-W, 2002).
27. Pfister, M., Labbé, L., Hammer, S. M., Mellors, J., Bennett, K. K., Rosenkranz, S. et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: adult AIDS clinical trial group study 398. Antimicrob. Agents Chemother. 47, 130-137 (2003).
28. Kappelhoff, B. S., van Leth, F., MacGregor, T. R., Lange, J., Beijnen, J. H. & Huitema, A. D. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir. Ther. 10, 145-155 (2005).
29. Tanabe, M., Ieiri, I., Nagata, N., Inoue, K., Ito, S., Kanamori, Y. et al. Expression of Pglycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance MDR1 gene. J . Pharmacol. Exp. Ther. 297, 1137-1143 (2001).
30. Koyama, T., Nakamura, T., Komoto, C., Sakaeda, T., Taniguchi, M., Okamura, N. et al. MDR1 T-129C polymorphism can be predictive of differentiation, and thereby prognosis of colorectal adenocarcinomas in Japanese. Biol. Pharm. Bull. 29, 1449-1453 (2006).
31. Taniguchi, S., Mochida, Y., Uchiumi, T., Tahira, T., Hayashi, K., Takagi, K. et al. Genetic polymorphism at the 5′ regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol. Cancer Ther. 2, 1351-1359 (2003).
32. Illmer, T., Schuler, U. S., Thiede, C., Schwarz, U. I., Kim, R. B., Gotthard, S. et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukaemia patients. Cancer Res. 62, 4955-4962 (2002).
33. Moriya, Y., Nakamura, T., Horinouchi, M., Sakaeda, T., Tamura, T., Aoyama, N. et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 25, 1356-1359 (2002).
34. Yi, S., Hong, K., Lim, H., Chung, J., Oh, D., Kim, J. et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin. Pharmacol. Ther. 76, 418-427 (2004).
35. Telenti, A. & Zanger, U. M. Pharmacogenetics of anti-HIV drugs. Annu. Rev. Pharmacol. 48, 227-256 (2007).
36. Lamba, V., Lamba, J., Yasuda, K., Strom, S., Davila, J., Hancock, M. L. et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. 307, 906-922 (2003).
37. Jacob, R. M., Johnstone, E. C., Neville, M. J. & Walton, R. T. Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin. Chem. 50, 1372-1377 (2004).
38. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Johne, A. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97, 3473-3478 (2000).